Related Experiment Video

Updated: Jun 6, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

Cynthia X Ma1, James W Janetka, Helen Piwnica-Worms

  • 1Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

Trends in Molecular Medicine
|November 20, 2010
PubMed

Insights

Checkpoint Kinase 1 (CHK1) inhibitors cause cell death in p53-deficient cancers by disrupting cell cycle checkpoints. These CHK1 inhibitors show promise in sensitizing tumors to cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • TP53 mutations or regulatory pathway disruptions are common in human cancers.
  • p53-deficient cancer cells rely on CHK1 for cell cycle checkpoint activation.
  • CHK1 inhibition triggers mitotic catastrophe and cell death in p53-deficient tumors.

Purpose of the Study:

  • To review recent advancements in the development of CHK1 inhibitors.
  • To discuss the application of CHK1 inhibitors as cancer therapeutics.
  • To summarize current controversies surrounding CHK1 inhibitor development.

Main Methods:

  • Literature review of preclinical and clinical studies on CHK1 inhibitors.
  • Analysis of mechanisms of action for CHK1 inhibition in cancer.
  • Evaluation of CHK1 inhibitors in combination with DNA-damaging agents and antimetabolites.

Main Results:

  • CHK1 inhibitors induce synthetic lethality in p53-deficient cancer cells.
  • Inhibition of CHK1 sensitizes tumors to various chemotherapeutic agents.
  • CHK1 inhibitors are under investigation in early-phase clinical trials for cancer treatment.

Conclusions:

  • CHK1 inhibitors represent a promising targeted therapy for p53-deficient cancers.
  • Further research is needed to optimize the clinical application of CHK1 inhibitors.
  • Understanding the role of p53 status is crucial for predicting response to CHK1 inhibitors.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...